Invesco
ACRS icon

Invesco’s Aclaris Therapeutics ACRS Stock Holding History

Invesco’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$806K Buy
214,935
+5,032
+2% +$17K ﹤0.01% 2962
2025
Q4 		$632K Buy
209,903
+47,440
+29% +$120K ﹤0.01% 3118
2025
Q3 		$309K Buy
162,463
+27,134
+20% +$47.3K ﹤0.01% 3406
2025
Q2 		$192K Buy
135,329
+78,250
+137% +$106K ﹤0.01% 3519
2025
Q1 		$87.3K Buy
57,079
+45,864
+409% +$97.8K ﹤0.01% 3645
2024
Q4 		$27.8K Buy
+11,215
New +$27.9K ﹤0.01% 3732
2024
Q2 		– Sell
-30,498
Closed -$37.8K – 3871
2024
Q1 		$37.8K Sell
30,498
-1,159
-4% -$1.38K ﹤0.01% 3821
2023
Q4 		$33.2K Sell
31,657
-8,061
-20% -$24.6K ﹤0.01% 3783
2023
Q3 		$272K Sell
39,718
-851
-2% -$7.27K ﹤0.01% 3488
2023
Q2 		$421K Buy
40,569
+2,432
+6% +$22K ﹤0.01% 3339
2023
Q1 		$309K Buy
38,137
+10,354
+37% +$131K ﹤0.01% 3490
2022
Q4 		$438K Sell
27,783
-1,202
-4% -$19.3K ﹤0.01% 3340
2022
Q3 		$456K Buy
28,985
+4,216
+17% +$66.4K ﹤0.01% 3292
2022
Q2 		$346K Buy
24,769
+693
+3% +$9.71K ﹤0.01% 3512
2022
Q1 		$415K Sell
24,076
-263
-1% -$3.59K ﹤0.01% 3484
2021
Q4 		$354K Sell
24,339
-414,463
-94% -$6.28M ﹤0.01% 3540
2021
Q3 		$7.9M Buy
438,802
+418,886
+2,103% +$6.72M ﹤0.01% 2134
2021
Q2 		$350K Sell
19,916
-887,118
-98% -$20.2M ﹤0.01% 3566
2021
Q1 		$22.9M Buy
907,034
+813,562
+870% +$15.9M 0.01% 1447
2020
Q4 		$605K Sell
93,472
-4,044
-4% -$17.1K ﹤0.01% 3147
2020
Q3 		$251K Sell
97,516
-3,224
-3% -$7.21K ﹤0.01% 3381
2020
Q2 		$163K Sell
100,740
-14,017
-12% -$18.8K ﹤0.01% 3526
2020
Q1 		$119K Buy
114,757
+87,540
+322% +$119K ﹤0.01% 3530
2019
Q4 		$51K Sell
27,217
-1,805
-6% -$2.99K ﹤0.01% 3629
2019
Q3 		$31K Sell
29,022
-1,140
-4% -$1.62K ﹤0.01% 3662
2019
Q2 		$66K Sell
30,162
-1,072
-3% -$5.84K ﹤0.01% 3699
2019
Q1 		$187K Buy
+31,234
New +$207K ﹤0.01% 3631
2018
Q4 		– Sell
-544,334
Closed -$7.9M – 3813
2018
Q3 		$7.9M Sell
544,334
-31,631
-5% -$542K ﹤0.01% 1868
2018
Q2 		$11.5M Buy
575,965
+11
+0% +$203 ﹤0.01% 1587
2018
Q1 		$10.1M Sell
575,954
-9,300
-2% -$197K ﹤0.01% 1532
2017
Q4 		$14.4M Buy
585,254
+57
+0% +$1.39K 0.01% 1385
2017
Q3 		$15.1M Sell
585,197
-24,403
-4% -$654K 0.01% 1340
2017
Q2 		$16.5M Sell
609,600
-45,376
-7% -$1.23M 0.01% 1276
2017
Q1 		$19.5M Buy
654,976
+30,653
+5% +$884K 0.01% 1183
2016
Q4 		$16.9M Buy
+624,323
New +$15.9M 0.01% 1216

Other funds holding ACRS

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Invesco's ACRS Position: Q1 2026 in Review

Invesco increased its Aclaris Therapeutics (ACRS) stake by 2.4% in Q1 2026, buying an estimated $17K and bringing the position to 214,935 shares worth $806K. The position accounts for ﹤0.01% of the portfolio, ranked #2962.

Invesco first reported a position in ACRS in Q4 2016 and has held it in 35 quarters since. The position peaked at $22.9M in Q1 2021. 136 funds tracked by Wall St. Rank hold ACRS as of Q1 2026.

  • Invesco held 214,935 shares of Aclaris Therapeutics worth $806K as of Q1 2026.
  • Invesco bought 5,032 Aclaris Therapeutics shares in Q1 2026, an estimated $17K.
  • Aclaris Therapeutics made up ﹤0.01% of Invesco's portfolio in Q1 2026, its #2962 holding.
  • Invesco first reported a position in Aclaris Therapeutics in Q4 2016 and has held it in 35 quarters since.
  • Invesco's Aclaris Therapeutics position peaked at $22.9M in Q1 2021.
  • 136 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q1 2026.

Based on Invesco's 13F filing for Q1 2026, filed 12 May 2026.